Skip to content
lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
DBV Technologies S.A.
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
June 2, 2026
DBV Technologies Reports First Quarter 2026 Financial Results
April 30, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
April 2, 2026
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
March 26, 2026
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
March 24, 2026
DBV Technologies to Participate in Upcoming March Investor Conferences
March 4, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
March 3, 2026
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
February 28, 2026
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d’euros suite à l’exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025
February 25, 2026
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
February 13, 2026
1
2
Next Page
→